TY  - EJOU
AU  - LI, YUZHENG 
AU  - YU, LILI 
AU  - ZHOU, SHIYAO 
AU  - ZHOU, HUA 
AU  - WU, QIBIAO 

TI  - Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies
T2  - Oncology Research

PY  - 2025
VL  - 33
IS  - 6
SN  - 1555-3906

AB  -  <b>Background:</b> Non-small cell lung cancer (NSCLC) involves complex alterations in the epidermal growth factor receptor (EGFR) signaling pathway. This study aims to integrate multimodal omics analyses to evaluate and enhance EGFR-targeted therapies. <b>Methods:</b> We reviewed and synthesized omics data—including genomics, transcriptomics, proteomics, epigenomics, and metabolomics data—related to the EGFR pathway in NSCLC, examined the clinical outcomes of current therapies and proposed new treatment strategies. <b>Results:</b> Integrated omics analyses revealed the multifaceted role of EGFR in NSCLC. Transcriptomic analysis revealed gene expression alterations due to EGFR mutations, with upregulation of oncogenes and downregulation of tumor suppressors. Proteomics revealed complex interactions within the EGFR network, revealing cross-talk with other receptors. Epigenomics highlighted the impact of DNA methylation and histone modifications on EGFR and its downstream genes, whereas metabolomics demonstrated shifts in metabolic patterns essential for tumor growth. <b>Conclusion:</b> This study highlights the critical role of multimodal omics in understanding the molecular landscape of NSCLC, offering insights into more effective, personalized therapies. Future advancements in omic technologies and analysis are expected to significantly enhance NSCLC diagnosis and treatment.
KW  - Cancer therapy; Epidermal growth factor receptor (EGFR); Multiomics technologies; Non-small cell lung cancer (NSCLC); Targeted therapies

DO  - 10.32604/or.2025.059311